Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediatorsSuelen da Silva Gomes Dias, Patrı́cia T. Bozza, Vinícius Cardoso Soares et al.|PLoS Pathogens|2020Cited by 321
SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytesAndré C. Ferreira, Thiago Moreno L. Souza, Eugênio D. Hottz et al.|Cell Death Discovery|2021Cited by 279
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q. Sacramento, Thiago Moreno L. Souza, Gabrielle R. de Melo et al.|Scientific Reports|2017Cited by 243
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine ProductionNatalia Fintelman‐Rodrigues, Thiago Moreno L. Souza, Carolina Q. Sacramento et al.|Antimicrobial Agents and Chemotherapy|2020Cited by 142
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivoCaroline S. de Freitas, Thiago Moreno L. Souza, Luiza M. Higa et al.|PLoS neglected tropical diseases|2019Cited by 124